https://longevityprogress.com/videos2026-10-29T19:23:32.000Zdaily0.7 https://longevityprogress.com/videos/topic/biological-agedaily0.5 https://longevityprogress.com/videos/topic/plasma-and-young-blooddaily0.5 https://longevityprogress.com/videos/topic/thymusdaily0.5 https://longevityprogress.com/videos/topic/clearing-old-cellsdaily0.5 https://longevityprogress.com/videos/topic/drugs-and-supplementsdaily0.5 https://longevityprogress.com/videos/topic/science-of-agingdaily0.5 https://longevityprogress.com/videos/kejun-albert-ying-at-ardd2026-an-open-world-model-for-human-health-and-saqdwtsRuu42026-10-29T19:23:32.000Zmonthly0.5https://i.ytimg.com/vi/saqdwtsRuu4/hqdefault.jpgKejun (Albert) Ying at ARDD2026: An open world model for human health and mortalityKejun (Albert) Ying, Stanford University, presents at the 13th Aging Research and Drug Discovery Meeting: An open world model for human health and mortality Key takeaway: World models borrowed from video generation and protein language models can forecast individual disease trajectories and link protein structure to species lifespan. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Bioscience. #ARDD2026 #longevity #aging #drugdiscoveryhttps://www.youtube.com/embed/saqdwtsRuu42026-10-29T19:23:32.000Z https://longevityprogress.com/videos/hao-pei-at-ardd2026-aging-is-multidimensional-so-must-be-the-data-ntC_-TRnYe82026-10-29T17:34:55.000Zmonthly0.5https://i.ytimg.com/vi/ntC_-TRnYe8/hqdefault.jpgHao Pei at ARDD2026: Aging Is Multidimensional — So Must Be the DataHao Pei, MobiDrop, presents at the 13th Aging Research and Drug Discovery Meeting: Aging Is Multidimensional — So Must Be the Data: Co-registered Single-cell Readouts for Longevity Drug Discovery Key takeaway: Aging is dynamic and heterogeneous, so MobiDrop co-registers multiple readouts on the same single cells over time to generate AI-ready data. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Bioscience. #ARDD2026 #longevity #aging #drugdiscoveryhttps://www.youtube.com/embed/ntC_-TRnYe82026-10-29T17:34:55.000Z https://longevityprogress.com/videos/yuancheng-ryan-lu-at-ardd2026-functional-genomics-and-virtual-screenin-1VKV7UOA45Y2026-10-29T14:21:26.000Zmonthly0.5https://i.ytimg.com/vi/1VKV7UOA45Y/hqdefault.jpgYuancheng (Ryan) Lu at ARDD2026: Functional Genomics and Virtual ScreeningYuancheng (Ryan) Lu, Whitehead Institute, presents at the 13th Aging Research and Drug Discovery Meeting: Functional Genomics and Virtual Screening for Rejuvenation Factor Discovery Key takeaway: Functional genomics plus single-cell foundation models are finding rejuvenation factors safer than OSK that restore function in the eye and beyond. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Bioscience. #ARDD2026 #longevity #aging #drugdiscoveryhttps://www.youtube.com/embed/1VKV7UOA45Y2026-10-29T14:21:26.000Z https://longevityprogress.com/videos/capital-markets-and-philanthropy-panel-at-ardd2026-what-does-ai-in-lon-W49tPgYz8Rs2026-10-28T15:09:58.000Zmonthly0.5https://i.ytimg.com/vi/W49tPgYz8Rs/hqdefault.jpgCapital Markets and Philanthropy Panel at ARDD2026: What does AI in Longevity Biotech really need?Panel discussion with Youssof Mal (Hevolution), Sergey Jakimov (LongeVC), Martin Borch Jensen (Gordian Biotechnology), Todd White (The Thalion Initiative), and Michelle Kwok (Draper Associates), moderated by Uli Stilz (Flagship Pioneering), at the 13th Aging Research and Drug Discovery Meeting: What does AI in Longevity Biotech really need? And how can private capital markets and philanthropy fill this gap? Key takeaway: AI alone is not a moat; investors want proprietary, human-relevant data, validated assets in specific indications and causal, longitudinal data generation. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Friemanhttps://www.youtube.com/embed/W49tPgYz8Rs2026-10-28T15:09:58.000Z https://longevityprogress.com/videos/graeme-bainbridge-at-ardd2026-feline-longevity-6nYhdYhJCtw2026-10-27T19:05:34.000Zmonthly0.5https://i.ytimg.com/vi/6nYhdYhJCtw/hqdefault.jpgGraeme Bainbridge at ARDD2026: Feline LongevityGraeme Bainbridge, Dechra, presents at the 13th Aging Research and Drug Discovery Meeting: Feline Longevity: How an Animal Pharma company thinks about chronic diseases and Quality of Life Key takeaway: For cats, the goal is healthspan: shifting from symptom management to disease-modifying treatment of chronic disease. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Bioscience. #ARDD2026 #longevity #aging #drugdiscoveryhttps://www.youtube.com/embed/6nYhdYhJCtw2026-10-27T19:05:34.000Z https://longevityprogress.com/videos/philipp-gut-at-ardd2026-nutrition-to-slow-biological-aging-in-dogs-TRrLgi-Rc-c2026-10-27T15:45:12.000Zmonthly0.5https://i.ytimg.com/vi/TRrLgi-Rc-c/hqdefault.jpgPhilipp Gut at ARDD2026: Nutrition to slow biological aging in dogsPhilipp Gut, Nestlé Research, presents at the 13th Aging Research and Drug Discovery Meeting: Nutrition to slow biological aging in dogs Key takeaway: Phenotypic and epigenetic clocks respond to diet and predict outcomes in dogs, making them practical endpoints for longevity nutrition trials. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Bioscience. #ARDD2026 #longevity #aging #drugdiscoveryhttps://www.youtube.com/embed/TRrLgi-Rc-c2026-10-27T15:45:12.000Z https://longevityprogress.com/videos/vicky-yang-at-ardd2026-mitral-valve-prolapse-XiClONNH7xE2026-10-27T14:18:17.000Zmonthly0.5https://i.ytimg.com/vi/XiClONNH7xE/hqdefault.jpgVicky Yang at ARDD2026: Mitral valve prolapseVicky Yang, Tufts University, presents at the 13th Aging Research and Drug Discovery Meeting: Mitral valve prolapse: studying aging-associated cardiac changes in the dog model Key takeaway: Canine myxomatous mitral valve disease is driven by a macrophage–fibroblast feedback loop, offering targets that translate to human mitral valve prolapse. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Bioscience. #ARDD2026 #longevity #aging #drugdiscoveryhttps://www.youtube.com/embed/XiClONNH7xE2026-10-27T14:18:17.000Z https://longevityprogress.com/videos/dan-promislow-at-ardd2026-the-companion-dog-as-a-translational-model-o-e9ARSFLuqJY2026-10-26T19:45:44.000Zmonthly0.5https://i.ytimg.com/vi/e9ARSFLuqJY/hqdefault.jpgDan Promislow at ARDD2026: The Companion Dog as a Translational Model of AgingDan Promislow, HNRCA at Tufts University, presents at the 13th Aging Research and Drug Discovery Meeting: The Companion Dog as a Translational Model of Aging Key takeaways: – More than 55,000 dogs enrolled since 2020; a Precision Cohort of ~1,000 dogs gives annual biospecimens; data shared via the Broad's Terra. – NIA renewed funding for five more years; a new cohort of ~1,000 of the oldest U.S. dogs will get 30x genomes; the Precision Cohort could grow to 3,000 and add transcriptome, proteome and lipidome with more support. – Dogs with lower epigenetic age live longer; genes hypomethylated with age in dogs tend to rise in expression in aging humans. – 25 metabolites (enriched for kidney markers) predict mortality in dogs and in the same direction in humans, found with 2.6 years of follow-up vs. 8–25 in human studies. – GWAS linked a chromosome 25 SNP to kynurenic acid; coat "furnishing" genes (RSPO2, FGF5) also shift cystathionine, a cysteine precursor. – TRIAD rapamycin trial: target 580 dogs, over half enrolled, one year of drug and three years of follow-up, neurology and cardiology arms; safety excellent, efficacy in ~4 years. – Q&A: U.S. dogs are mostly sterilized, so intact-dog studies may suit France or Germany; owners skew white, wealthy and educated; no experimental drugs in owners' pets without lab-dog safety data. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its movehttps://www.youtube.com/embed/e9ARSFLuqJY2026-10-26T19:45:44.000Z https://longevityprogress.com/videos/joe-betts-lacroix-at-ardd2026-ai-for-rejuvenation-and-replacement-ther-xvdub-fU_X02026-10-26T17:15:34.000Zmonthly0.5https://i.ytimg.com/vi/xvdub-fU_X0/hqdefault.jpgJoe Betts-LaCroix at ARDD2026: AI for rejuvenation & replacement therapiesJoe Betts-LaCroix, Retro Biosciences, presents at the 13th Aging Research and Drug Discovery Meeting: AI for rejuvenation & replacement therapies Key takeaways: – Two strategies: replacement (young HSCs, microglia) and rejuvenation in place, aiming to add ~10 healthy years. – An autophagy-restoring small molecule is in Phase 1 in Australia, with a Phase 2 in Alzheimer’s planned for 2027. – A generative protein model produced engineered reprogramming transcription factors with improved performance; ~50% functional hit rate, with variants up to ~80% dissimilar from wild type. – Proposed that the FDA run predictive models confidentially on undisclosed trials to build trust in AI predictions. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, https://www.youtube.com/embed/xvdub-fU_X02026-10-26T17:15:34.000Z https://longevityprogress.com/videos/salah-mahmoudi-at-ardd2026-alphaforge-predicts-clinical-outcomes-Cz0l0hrpF7Q2026-10-26T15:39:40.000Zmonthly0.5https://i.ytimg.com/vi/Cz0l0hrpF7Q/hqdefault.jpgSalah Mahmoudi at ARDD2026: AlphaForge predicts clinical outcomesSalah Mahmoudi, SAISHO, presents at the 13th Aging Research and Drug Discovery Meeting: AlphaForge predicts clinical outcomes through multi-domain scientific reasoning Key takeaways: – Predicts clinical success and primary failure drivers from structure, target and disease alone. – Retrospective AUC 0.90 on 391 small-molecule programs; prospective AUC 0.886 on 83 programs after the model was frozen in January 2025. – Reported to outperform general LLMs by ≥29 points; identifies the primary failure reason in most cases (e.g., liver toxicity of sitaxentan). – Performance similar in trials of patients over 60. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Ahttps://www.youtube.com/embed/Cz0l0hrpF7Q2026-10-26T15:39:40.000Z https://longevityprogress.com/videos/jamie-heywood-at-ardd2026-reproducibility-and-scale-bound-individual-p-tED9nSzIYDk2026-10-23T19:07:41.000Zmonthly0.5https://i.ytimg.com/vi/tED9nSzIYDk/hqdefault.jpgJamie Heywood at ARDD2026: Reproducibility and scale bound Individual Physiology AIJamie Heywood, Alden Scientific, presents at the 13th Aging Research and Drug Discovery Meeting: Reproducibility and scale bound Individual Physiology AI: integrating genomic, antibody, protein and clinical data over time Key takeaways: – ~60,000 integrated samples, including ~3,000 replicates to quantify measurement variance; better sample handling reduced replicate CV from 33% to 23%. – Of the clocks tested, a protein age model was most accurate (~0.94) but offered little actionable guidance; glycan age tracked trajectory rather than position. – First antibody-based age clock built on 1,600 antigens in ~2,500 people. – UK Biobank variation compresses to ~256 latent variables; more than 90% of signal in his cohorts sits in core proteomic assays. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Lifehttps://www.youtube.com/embed/tED9nSzIYDk2026-10-23T19:07:41.000Z https://longevityprogress.com/videos/gang-liu-at-ardd2026-rushdata-high-throughput-experimental-data-for-ai-PjwTE6nAwlg2026-10-23T15:55:57.000Zmonthly0.5https://i.ytimg.com/vi/PjwTE6nAwlg/hqdefault.jpgGang Liu at ARDD2026: RushData: High-Throughput Experimental Data for AI-Driven Antibody DiscoveryGang Liu, BioIntron, presents at the 13th Aging Research and Drug Discovery Meeting: RushData: High-Throughput Experimental Data for AI-Driven Antibody Discovery Key takeaways: – AI has made antibody hits abundant; wet-lab validation is now the bottleneck. – Tests ~3,000 sequences per batch in CHO-K1 cells; supernatant data in 7 days, purified-sample affinity and developability data in 14 days. – Built on a facility producing more than 150,000 antibodies per year; outputs structured for retraining AI models. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScohttps://www.youtube.com/embed/PjwTE6nAwlg2026-10-23T15:55:57.000Z https://longevityprogress.com/videos/feixiong-cheng-at-ardd2026-ai4cure-ad-platform-for-alzheimers-disease-0EBT6T4E9Jg2026-10-22T19:39:27.000Zmonthly0.5https://i.ytimg.com/vi/0EBT6T4E9Jg/hqdefault.jpgFeixiong Cheng at ARDD2026: AI4Cure-AD Platform for Alzheimer's Disease Drug DevelopmentFeixiong Cheng, Cleveland Clinic, presents at the 13th Aging Research and Drug Discovery Meeting: AI4Cure-AD Platform for Alzheimer's Disease Drug Development Key takeaways: – Combines human genetics and multi-omics, deep phenotypes, AI target prediction, EHR data and validation in iPSC neurons and organoids. – Single-cell atlas of more than 2,200 individuals and ~40 million nuclei. – AI flagged sildenafil for repurposing; EHR analysis linked it to 30–40% lower Alzheimer’s risk, leading to a Phase 2 trial. – Genetics pointed to EPHB2 as a causal target; editing in human iPSC neurons was neuroprotective and reduced tau hyperphosphorylation. – An EPHB2 inhibitor reduced amyloid and neuroinflammation in mice, completed Phase 1a and is in a ~30-person Phase 1b pilot focused on CSF and plasma biomarkers. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Theraphttps://www.youtube.com/embed/0EBT6T4E9Jg2026-10-22T19:39:27.000Z https://longevityprogress.com/videos/max-unfried-at-ardd2026-biomedical-mega-projects-v36sJyfF8aM2026-10-22T17:33:50.000Zmonthly0.5https://i.ytimg.com/vi/v36sJyfF8aM/hqdefault.jpgMax Unfried at ARDD2026: Biomedical Mega ProjectsMax Unfried, National University of Singapore, presents at the 13th Aging Research and Drug Discovery Meeting: Biomedical Mega Projects: The Necessary Infrastructure To Understand The Biology Of Aging and Maximum Lifespan Key takeaways: – Curing age-related diseases alone is unlikely to extend maximum human lifespan (~120 years). – Called for long-horizon, internationally funded “mega projects” on the scale of physics. – Thalion plans standardized tissue sampling across all organs from ~200 mammal species (~60 specimens per species, across ages) with multi-omics, to build an AI-ready comparative dataset. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Aldehttps://www.youtube.com/embed/v36sJyfF8aM2026-10-22T17:33:50.000Z https://longevityprogress.com/videos/jonathan-gootenberg-at-ardd2026-proteomic-clocks-for-target-nomination-bSmqlBQQjuY2026-10-22T15:39:22.000Zmonthly0.5https://i.ytimg.com/vi/bSmqlBQQjuY/hqdefault.jpgJonathan Gootenberg at ARDD2026: Proteomic Clocks for Target NominationJonathan Gootenberg, Harvard Medical School, presents at the 13th Aging Research and Drug Discovery Meeting: Proteomic Clocks for Target Nomination Key takeaways: – Proteomics offers interpretable, organ-resolved signals that correlate strongly with age and disease risk. – Clocks built on biologically defined protein subsets transfer between UK Biobank and All of Us; organ clocks best predict related outcomes (e.g., heart clock for cardiovascular mortality). – Drug effects need careful interpretation: metformin raises clock age through GDF15 induction, a marker effect. – Mendelian randomization separates drivers from markers: GDF15 is strongly linked to mortality but appears non-causal, while FES and FURIN show causal evidence. – Clocks may serve as surrogate endpoints only after rigorous validation, since they can move without outcomes changing, and vice versa. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, Thttps://www.youtube.com/embed/bSmqlBQQjuY2026-10-22T15:39:22.000Z https://longevityprogress.com/videos/alex-zhavoronkov-at-ardd2026-aging-first-drug-discovery-with-mmai-and-D5ewS091vxE2026-10-22T14:20:18.000Zmonthly0.5https://i.ytimg.com/vi/D5ewS091vxE/hqdefault.jpgAlex Zhavoronkov at ARDD2026: Aging-first Drug Discovery with MMAI and Longevity Foundation ModelsAlex Zhavoronkov, Insilico Medicine, presents at the 13th Aging Research and Drug Discovery Meeting: Aging-first Drug Discovery with MMAI and Longevity Foundation Models Key takeaways: – Aging clocks have evolved from “mechanical watches” (early epigenetic clocks) to multi-omic foundation models such as Insilico’s Precious GPT series. – Benchmark of 25,000 prompts across 18 frontier models: smaller fine-tuned models outperformed large LLMs on biological tasks. – Future: large orchestrator models coordinating many specialized agents for continuous research. – AI is validated only when it repeatedly yields successful drug candidates; ~$5M estimated to reach a developmental candidate. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cathttps://www.youtube.com/embed/D5ewS091vxE2026-10-22T14:20:18.000Z https://longevityprogress.com/videos/matthew-oconnor-at-ardd2026-removing-oxidized-cholesterol-zg5mDDcVbXI2026-10-21T19:30:34.000Zmonthly0.5https://i.ytimg.com/vi/zg5mDDcVbXI/hqdefault.jpgMatthew O'Connor at ARDD2026: Removing Oxidized CholesterolMatthew O'Connor, Cyclarity Therapeutics, presents at the 13th Aging Research and Drug Discovery Meeting: Removing Oxidized Cholesterol: Clinical Trials for a New Approach to Cardiometabolic and Age-Related Disease Key takeaway: An engineered cyclodextrin dimer selectively clears oxidized cholesterol and reverses foam cells; Phase 1 showed excellent safety and dose-dependent target engagement. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Bioscience. #ARDD2026 #longevity #aginhttps://www.youtube.com/embed/zg5mDDcVbXI2026-10-21T19:30:34.000Z https://longevityprogress.com/videos/francisco-leon-at-ardd2026-preserving-and-restoring-the-thymus-for-hea-rMu56nLLHOM2026-10-21T18:08:17.000Zmonthly0.5https://i.ytimg.com/vi/rMu56nLLHOM/hqdefault.jpgFrancisco Leon at ARDD2026: Preserving and restoring the thymus for healthspan extensionFrancisco Leon, Tolerance Bio, presents at the 13th Aging Research and Drug Discovery Meeting: Preserving and restoring the thymus for healthspan extension Key takeaway: Thymic involution is a key driver of immune aging; Tolerance Bio aims to preserve the thymus with anti-IL-33 and regenerate it with IL-7. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Bioscience. #ARDD2026 #longevity #aging #drugdiscoveryhttps://www.youtube.com/embed/rMu56nLLHOM2026-10-21T18:08:17.000Z https://longevityprogress.com/videos/george-daley-at-ardd2026-opening-remarks-from-the-dean-of-harvard-medi-O-6NG0v35hQ2026-10-21T16:15:23.000Zmonthly0.5https://i.ytimg.com/vi/O-6NG0v35hQ/hqdefault.jpgGeorge Daley at ARDD2026: Opening Remarks from the Dean of Harvard Medical SchoolGeorge Daley, Harvard Medical School, opens the 13th Aging Research and Drug Discovery Meeting. Key takeaway: Aging research has immense potential, but the field must resist hype, uphold rigor and communicate responsibly. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Bioscience. #ARDD2026 #longevity #aging #drugdiscoveryhttps://www.youtube.com/embed/O-6NG0v35hQ2026-10-21T16:15:23.000Z https://longevityprogress.com/videos/kirsten-seale-at-ardd2026-from-infrastructure-to-insight-aEjRuMri1d82026-10-21T14:20:03.000Zmonthly0.5https://i.ytimg.com/vi/aEjRuMri1d8/hqdefault.jpgKirsten Seale at ARDD2026: From Infrastructure to InsightKirsten Seale, TruDiagnostic, presents at the 13th Aging Research and Drug Discovery Meeting: From Infrastructure to Insight: A Large-Scale DNA methylation Asset and Epigenetic Insights from a Longitudinal GLP-1 Trial Key takeaway: A single DNA methylation assay can serve as a broad trial endpoint, tracking biological age, surrogate biomarkers and future disease risk, as shown in a tirzepatide trial. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Bioscience. #ARDD2026 #longevithttps://www.youtube.com/embed/aEjRuMri1d82026-10-21T14:20:03.000Z https://longevityprogress.com/videos/kevin-duffin-at-ardd2026-modulation-of-aging-clocks-by-the-glp-1-gip-d-IzvidXK4baM2026-10-20T20:29:35.000Zmonthly0.5https://i.ytimg.com/vi/IzvidXK4baM/hqdefault.jpgKevin Duffin at ARDD2026: Modulation of Aging Clocks by the GLP-1/GIP dual agonist, TirzepatideKevin Duffin, Eli Lilly, presents at the 13th Aging Research and Drug Discovery Meeting: Modulation of Aging Clocks by the GLP-1/GIP dual agonist, Tirzepatide Key takeaway: In a SURMOUNT-5 sub-study, 72 weeks of tirzepatide slowed multiple epigenetic clocks, including organ-specific clocks, though some methylation-based predictions missed. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Bioscience. #ARDD2026 #longevity #aging #drugdiscoveryhttps://www.youtube.com/embed/IzvidXK4baM2026-10-20T20:29:35.000Z https://longevityprogress.com/videos/james-kirkland-at-ardd2026-new-clinical-trials-strategies-for-gerother-p4jFpkGF1QE2026-10-20T17:22:50.000Zmonthly0.5https://i.ytimg.com/vi/p4jFpkGF1QE/hqdefault.jpgJames Kirkland at ARDD2026: New Clinical Trials Strategies for GerotherapeuticsJames Kirkland, Cedars-Sinai Medical Center, presents at the 13th Aging Research and Drug Discovery Meeting: New Clinical Trials Strategies for Gerotherapeutics: The Translational Geroscience Network Key takeaway: Small, coordinated trials are showing safety and early efficacy of targeting fundamental aging processes while building responsive biomarker sets. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Bioscience. #ARDD2026 #longevity #aging #drugdiscoveryhttps://www.youtube.com/embed/p4jFpkGF1QE2026-10-20T17:22:50.000Z https://longevityprogress.com/videos/wei-wu-he-at-ardd2026-human-longevity-longitudinal-cohort--eUPDH748xg2026-10-20T17:03:17.000Zmonthly0.5https://i.ytimg.com/vi/-eUPDH748xg/hqdefault.jpgWei-Wu He at ARDD2026: Human Longevity Longitudinal CohortWei-Wu He, Human Longevity, Inc., presents at the 13th Aging Research and Drug Discovery Meeting: Human Longevity Longitudinal Cohort: From Genome to Digital Health Twin: Building the Future of Precision Longevity Key takeaway: Whole-genome sequencing plus AI enables earlier prediction and prevention of disease, potentially pushing average life expectancy toward 100. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Bioscience. #ARDD2026 #longevity #aging #drugdiscoveryhttps://www.youtube.com/embed/-eUPDH748xg2026-10-20T17:03:17.000Z https://longevityprogress.com/videos/morten-scheibye-knudsen-at-ardd2026-quantifying-and-targeting-aging-ph-3R_WCurGe782026-10-20T16:06:14.000Zmonthly0.5https://i.ytimg.com/vi/3R_WCurGe78/hqdefault.jpgMorten Scheibye-Knudsen at ARDD2026: Quantifying and targeting aging phenotypes driven by DNA damageMorten Scheibye-Knudsen, University of Copenhagen, presents at the 13th Aging Research and Drug Discovery Meeting: Quantifying and targeting aging phenotypes driven by DNA damage Key takeaway: Phenotypic biomarkers from photos and cell morphology predict hard outcomes, and compounds that trigger DNA-damage signaling without damage reversed senescence and rescued Alzheimer's-model mice. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Bioscience. #ARDD2026 #longevity #aging #drugdhttps://www.youtube.com/embed/3R_WCurGe782026-10-20T16:06:14.000Z https://longevityprogress.com/videos/fda-panel-at-ardd2026-matching-clinical-trials-of-therapeutics-and-reg-aY3W6baq9MU2026-10-20T15:06:33.000Zmonthly0.5https://i.ytimg.com/vi/aY3W6baq9MU/hqdefault.jpgFDA Panel at ARDD2026: Matching Clinical Trials of Therapeutics & Regulatory MandatesPanel discussion with Jeffrey Siegel, Justin Penzenstadler, Lowell M. Zeta, and Steven Kozlowski of the FDA, moderated by Andrew Brack, ARPA-H, at the 13th Aging Research and Drug Discovery Meeting: Matching Clinical Trials of Therapeutics & Regulatory Mandates Key takeaway: FDA officials signaled that progress does not hinge on calling aging a disease; validated, function-based endpoints and shared data are the way forward. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founded by Alex Zhavoronkov in 2014. Following years of growth in Europe, ARDD made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1-3, 2026. The conference opened with a ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, to commemorate its move to the US. Follow us for updates on ARDD 2027 in Boston! Website: https://agingpharma.org/ LinkedIn: https://www.linkedin.com/company/agingpharma/ ARDD 2026 was organized by @InsilicoMedicine with support from Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Human Longevity, Dior, Maxwell Biosciences, Microsoft, BioAge, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, Institute for Healthier Living Abu Dhabi, TruDiagnostic, Cambrian Bio, ARTAN Bio, bio.xyz, Cyclarity Therapeutics, Rubedo Life Sciences, Biocytogen, SAISHO, Life Biosciences, Shift Bioscience, Synaro Capital, Biointron, The Cat Health Company, PranaGen Bioscience, Rhizome, Einstein BIO-VITAL Program, Alden Scientific, BDO, Cole-Frieman & Mallon, Morgan Stanley, Estée Lauder Companies, ICFSR, QuadraScope, BrainKey, Retro Biosciences, Compound Life, MobiDrop, Trilliome, and Nagi Biosciehttps://www.youtube.com/embed/aY3W6baq9MU2026-10-20T15:06:33.000Z https://longevityprogress.com/videos/when-zombie-cells-attack-afar-webinar-PLKbsi2IQec2026-10-13T17:11:00.000Zmonthly0.5https://i.ytimg.com/vi/PLKbsi2IQec/hqdefault.jpgWhen Zombie Cells Attack | AFAR WebinarWhen Zombie Cells Attack: How Geroscience is Fighting Back to Extend Healthspan | AFAR and Nathan Shock Centers Webinar (October 8, 2026) It’s not just a ghost story: zombie cells are real and increasing all the time through the process of cellular aging, or cellular senescence. In this webinar presented by AFAR and Nathan Shock Centers Coordinating Center (NSC3), AFAR Scientific Director Steven N. Austad, PhD, moderated a discussion exploring how a deeper understanding of senescent cells could help promote a longer healthspan. Darren J. Baker, PhD, of Mayo Clinic; AFAR Grantee Anthony Covarrubias, PhD, of the UCLA Broad Stem Cell Research Center; and 2018 AFAR Cristofalo Award recipient Laura Niedernhofer, MD, PhD, Co-Director of the Minnesota Nathan Shock Center share insights. Learn more about aging research: https://www.afar.org/ Follow AFAR on social media: Facebook: American Federation for Aging Research LinkedIn: American Federation for Aging Researchhttps://www.youtube.com/embed/PLKbsi2IQec2026-10-13T17:11:00.000Z https://longevityprogress.com/videos/oct-7-2026-what-the-ovary-teaches-us-about-aging-for-females-and-males-d2bhWURzRV82026-10-07T20:37:49.000Zmonthly0.5https://i.ytimg.com/vi/d2bhWURzRV8/hqdefault.jpgOct 7, 2026: What the Ovary Teaches Us About Aging – For Females and Males; Francesca Duncan, PhDSpeaker, Francesca Duncan, PhD; Associate Professor in Residence, Buck Institute; Associate Professor, Northwestern Universityhttps://www.youtube.com/embed/d2bhWURzRV82026-10-07T20:37:49.000Z https://longevityprogress.com/videos/can-these-pricey-hospital-programs-improve-longevity-fn0TZR3KSss2026-10-06T14:15:03.000Zmonthly0.5https://i.ytimg.com/vi/fn0TZR3KSss/hqdefault.jpgCan these pricey hospital programs improve longevity?For patients willing to pay thousands of dollars out of pocket, prestigious hospitals across the country are offering a new speciality - longevity. Private pay longevity clinics promise to monitor all sorts of health indicators and provide guidance on how to live a longer, healthier life. A couple of weeks ago, I tagged along with STAT commercial determinants of health report Sarah Todd as she tested out one of these new clinics at Weill Cornell Medicine in New York City. At Weill, Sarah underwent a battery of physical, written, and blood tests, performed frog jumps, ran down a hallway and wore a VO2 max mask that made her feel “like and elephant.” In this new STATus Report, I chat with Sarah about why hospitals are joining in on the longevity scene, why these programs have been facing some criticism, what she learned about her own health, and more. 0:00 Can longevity clinics help you live longer? 0:55 Trying a longevity assessment 1:54 What happens at a longevity clinic? 2:35 Sarah’s surprising test results 3:34 Why VO2 max matters 4:25 The anxiety of extensive health testing 5:35 Why hospitals are opening longevity clinics 6:38 Who can afford longevity medicine? 8:29 Do these programs actually work? 9:14 When testing gets ahead of the science 10:39 The business of longevity 11:13 Sarah’s lifestyle changeshttps://www.youtube.com/embed/fn0TZR3KSss2026-10-06T14:15:03.000Z https://longevityprogress.com/videos/adam-kroetsch-clinical-trial-abundance-what-it-means-why-we-need-it-an-vKH2eLxlaFI2026-09-23T10:40:07.000Zmonthly0.5https://i.ytimg.com/vi/vKH2eLxlaFI/hqdefault.jpgAdam Kroetsch | Clinical Trial Abundance: What it Means, Why We Need It, and How We Get There*Subscribe to Foresight Longevity Biotechnology Seminar Group:* https://foresight.org/seminar/longevity-biotechnology-seminar-group/ Supporting scientists, entrepreneurs, funders, and institutional partners in advancing biotechnology to reverse aging, extend human healthspan, and improve the human condition. This group is sponsored by 100 Plus Capital. http://100pluscap.com/ *Adam Kroetsch | Clinical Trial Abundance: What it Means, Why We Need It, and How We Get There* Abstract: In recent decades, drug discovery has been transformed by scientific advances, including AI. But increasingly, our ability to design drugs and generate hypotheses is outpacing our ability to test them. Clinical trials have become the critical bottleneck to medical advances. That's why we are advocating for clinical trial abundance: a focus on making clinical trials cheaper, faster, and more abundant - and more capable of generating useful clinical evidence. In my talk, I'll discuss the barriers that hold back clinical trial abundance, and how we can address them; including what FDA and policymakers can do. I'll discuss potential reforms to early-phase clinical trials, as well as ways to improve our clinical trial infrastructure and operations in the US. I'll put these proposals for reform in the context of two key developments: the rise of artificial intelligence, and the increasingly important role that China is playing in clinical trials. I'll also talk about drug regulation more broadly: depending on how we design our regulations, they can either hold back innovation or enable it. Bio: Adam Kroetsch is a senior biotechnology fellow at the Institute for Progress (IFP), a non-partisan think tank focused on innovation policy. For much of his career, Adam has focused on ways to improve our systems for generating and evaluating clinical evidence, including clinical trials and real-world data. Prior to joining IFP, Adam served as a deputy office director at the FDA's Center for Drug Evahttps://www.youtube.com/embed/vKH2eLxlaFI2026-09-23T10:40:07.000Z https://longevityprogress.com/videos/sept-2-2026-brain-aging-may-be-more-malleable-than-we-thought-tony-wys-ot6VwMuvqXU2026-09-02T21:08:23.000Zmonthly0.5https://i.ytimg.com/vi/ot6VwMuvqXU/hqdefault.jpgSept 2, 2026: Brain Aging May Be More Malleable Than We Thought; Tony Wyss-Coray, PhDSpeaker: Tony Wyss-Coray, PhD; Professor, Stanford Universityhttps://www.youtube.com/embed/ot6VwMuvqXU2026-09-02T21:08:23.000Z https://longevityprogress.com/videos/preserving-brain-health-advances-in-aging-research-and-biotech-afar-we-zT8yY6nt_qA2026-07-23T20:43:20.000Zmonthly0.5https://i.ytimg.com/vi/zT8yY6nt_qA/hqdefault.jpgPreserving Brain Health: Advances in Aging Research and Biotech | AFAR WebinarJuly 22 is World Brain Day, a time to celebrate the significant scientific advancements that have been made in better understanding the brain. Research on cognitive aging is deepening our understanding of when and how the brain becomes vulnerable and offering clearer targets to protect cognitive health across the lifespan. At the same time, technological advances are helping identify, diagnose, and forecast brain activity and biological factors that impact cognitive changes. To explore the progress in brain health science, join the American Federation for Aging Research (AFAR) and the McKnight Brain Research Foundation (MBRF) for a free webinar pairing recipients of the McKnight Brain Research Foundation Innovator Awards in Cognitive Aging and Memory Loss with neurotech leaders for a conversation grounded in promising research and science-backed tools.https://www.youtube.com/embed/zT8yY6nt_qA2026-07-23T20:43:20.000Z https://longevityprogress.com/videos/unlock-your-phenomes-secrets-biorhythm-data-explained-PX1EMPPnOKs2026-07-05T03:48:06.000Zmonthly0.5https://i.ytimg.com/vi/PX1EMPPnOKs/hqdefault.jpgUnlock Your Phenome's Secrets Biorhythm Data ExplainedDr. Matt Kaeberlein interviews longevity scientist and two-time world-champion rower Brianna Stubbs at the 2026 American Aging Association Annual Meeting. Catch the full interview here: https://youtu.be/kM6wL5dCq3shttps://www.youtube.com/embed/PX1EMPPnOKs2026-07-05T03:48:06.000Z https://longevityprogress.com/videos/aging-research-the-golden-era-of-discovery-t3LUDGekNTo2026-07-05T03:47:26.000Zmonthly0.5https://i.ytimg.com/vi/t3LUDGekNTo/hqdefault.jpgAging Research The Golden Era of DiscoveryDr. Matt Kaeberlein interviews longevity scientist and two-time world-champion rower Brianna Stubbs at the 2026 American Aging Association Annual Meeting. Catch the full interview here: https://youtu.be/kM6wL5dCq3shttps://www.youtube.com/embed/t3LUDGekNTo2026-07-05T03:47:26.000Z https://longevityprogress.com/videos/ketones-and-frailty-20-week-arpa-study-unveiled-BRHs5N8eyzk2026-07-05T03:46:43.000Zmonthly0.5https://i.ytimg.com/vi/BRHs5N8eyzk/hqdefault.jpgKetones & Frailty 20 Week ARPA Study UnveiledDr. Matt Kaeberlein interviews longevity scientist and two-time world-champion rower Brianna Stubbs at the 2026 American Aging Association Annual Meeting. Catch the full interview here: https://youtu.be/kM6wL5dCq3shttps://www.youtube.com/embed/BRHs5N8eyzk2026-07-05T03:46:43.000Z https://longevityprogress.com/videos/intrinsic-capacity-whos-5-domains-explained-VuD8bu0V8NE2026-07-05T03:46:13.000Zmonthly0.5https://i.ytimg.com/vi/VuD8bu0V8NE/hqdefault.jpgIntrinsic Capacity WHO's 5 Domains ExplainedDr. Matt Kaeberlein interviews longevity scientist and two-time world-champion rower Brianna Stubbs at the 2026 American Aging Association Annual Meeting. Catch the full interview here: https://youtu.be/kM6wL5dCq3shttps://www.youtube.com/embed/VuD8bu0V8NE2026-07-05T03:46:13.000Z https://longevityprogress.com/videos/functional-clock-predict-health-outcomes-20-years-ahead-OOTmvKNc9Tc2026-07-05T03:45:48.000Zmonthly0.5https://i.ytimg.com/vi/OOTmvKNc9Tc/hqdefault.jpgFunctional Clock Predict Health Outcomes 20 Years AheadDr. Matt Kaeberlein interviews longevity scientist and two-time world-champion rower Brianna Stubbs at the 2026 American Aging Association Annual Meeting. Catch the full interview here: https://youtu.be/kM6wL5dCq3shttps://www.youtube.com/embed/OOTmvKNc9Tc2026-07-05T03:45:48.000Z https://longevityprogress.com/videos/unlock-your-health-intervene-before-disease-strikes-x__XCa94NgU2026-07-05T03:45:18.000Zmonthly0.5https://i.ytimg.com/vi/x__XCa94NgU/hqdefault.jpgUnlock Your Health Intervene Before Disease StrikesDr. Matt Kaeberlein interviews longevity scientist and two-time world-champion rower Brianna Stubbs at the 2026 American Aging Association Annual Meeting. Catch the full interview here: https://youtu.be/kM6wL5dCq3shttps://www.youtube.com/embed/x__XCa94NgU2026-07-05T03:45:18.000Z https://longevityprogress.com/videos/arpa-h-funds-prosper-revolutionizing-aging-and-health-GIV_G46q3BA2026-07-04T17:48:17.000Zmonthly0.5https://i.ytimg.com/vi/GIV_G46q3BA/hqdefault.jpgARPA H Funds PROSPER Revolutionizing Aging & HealthDr. Matt Kaeberlein interviews longevity scientist and two-time world-champion rower Brianna Stubbs at the 2026 American Aging Association Annual Meeting. Catch the full interview here: https://youtu.be/kM6wL5dCq3shttps://www.youtube.com/embed/GIV_G46q3BA2026-07-04T17:48:17.000Z https://longevityprogress.com/videos/arpa-h-prosper-revolutionizing-aging-and-longevity-RRHMgtKSFHw2026-07-04T17:47:37.000Zmonthly0.5https://i.ytimg.com/vi/RRHMgtKSFHw/hqdefault.jpgARPA H PROSPER Revolutionizing Aging and LongevityDr. Matt Kaeberlein interviews longevity scientist and two-time world-champion rower Brianna Stubbs at the 2026 American Aging Association Annual Meeting. Catch the full interview here: https://youtu.be/kM6wL5dCq3shttps://www.youtube.com/embed/RRHMgtKSFHw2026-07-04T17:47:37.000Z https://longevityprogress.com/videos/exercise-vs-genetics-the-real-secret-to-healthy-aging-TU1wNSDac7s2026-07-04T17:46:59.000Zmonthly0.5https://i.ytimg.com/vi/TU1wNSDac7s/hqdefault.jpgExercise vs Genetics The REAL Secret to Healthy AgingDr. Matt Kaeberlein interviews longevity scientist and two-time world-champion rower Brianna Stubbs at the 2026 American Aging Association Annual Meeting. Catch the full interview here: https://youtu.be/kM6wL5dCq3shttps://www.youtube.com/embed/TU1wNSDac7s2026-07-04T17:46:59.000Z https://longevityprogress.com/videos/launching-clinical-trials-from-zero-to-irb-approved-FN9OWa05DT42026-07-04T17:46:06.000Zmonthly0.5https://i.ytimg.com/vi/FN9OWa05DT4/hqdefault.jpgLaunching Clinical Trials From Zero to IRB ApprovedDr. Matt Kaeberlein interviews longevity scientist and two-time world-champion rower Brianna Stubbs at the 2026 American Aging Association Annual Meeting. Catch the full interview here: https://youtu.be/kM6wL5dCq3shttps://www.youtube.com/embed/FN9OWa05DT42026-07-04T17:46:06.000Z https://longevityprogress.com/videos/the-20-year-aging-clock-65O7MP7WGyc2026-07-04T17:44:33.000Zmonthly0.5https://i.ytimg.com/vi/65O7MP7WGyc/hqdefault.jpgThe 20 Year Aging ClockDr. Matt Kaeberlein interviews longevity scientist and two-time world-champion rower Brianna Stubbs at the 2026 American Aging Association Annual Meeting. Catch the full interview here: https://youtu.be/kM6wL5dCq3shttps://www.youtube.com/embed/65O7MP7WGyc2026-07-04T17:44:33.000Z https://longevityprogress.com/videos/exercise-reverses-cellular-aging-clinical-trial-results-q8KGHzw7yHw2026-07-04T17:43:10.000Zmonthly0.5https://i.ytimg.com/vi/q8KGHzw7yHw/hqdefault.jpgExercise Reverses Cellular Aging Clinical Trial ResultsDr. Matt Kaeberlein interviews longevity scientist and two time world-champion rower Brianna Stubbs at the 2026 American Aging Association Annual Meeting. Catch the full interview here: https://youtu.be/kM6wL5dCq3shttps://www.youtube.com/embed/q8KGHzw7yHw2026-07-04T17:43:10.000Z https://longevityprogress.com/videos/july-1-2026-older-people-are-happier-laura-carstensen-phd-kD8auNta0ws2026-07-01T21:21:26.000Zmonthly0.5https://i.ytimg.com/vi/kD8auNta0ws/hqdefault.jpgJuly 1, 2026: Older People are Happier! Laura Carstensen, PhDSpeaker: Laura Carstensen, PhD, Founding Director, Stanford Center on Longevityhttps://www.youtube.com/embed/kD8auNta0ws2026-07-01T21:21:26.000Z https://longevityprogress.com/videos/q-and-a-with-eric-and-brianna-m4hrM3l4JqY2026-06-24T12:15:26.000Zmonthly0.5https://i.ytimg.com/vi/m4hrM3l4JqY/hqdefault.jpgQ&A with Eric and BriannaIn the final episode of season 3 we answer your biggest aging questions, from whether there is a single root cause of aging to why different organs fail in different ways. We also dig into what it would take to run human trials that prove real healthspan gains while staying honest about biomarkers, animal data, and online misinformation. Eric Verdin, MD and Brianna Stubbs, PhD Dr. Eric Verdin is President and CEO of the Buck Institute for Research on Aging and an internationally recognized physician-scientist whose research focuses on the molecular mechanisms of aging, metabolism, and the immune system. A native of Belgium, he earned his medical degree from the University of Liege and completed additional clinical and research training at Harvard Medical School. He has published more than 300 scientific papers, holds 18 patents, and is a member of several prestigious scientific organizations. Dr. Brianna Stubbs is a Lead Translational Scientist at the Buck Institute and a world expert in exogenous ketone metabolism and its implications for performance, resilience, and healthy aging. She earned her PhD in metabolic physiology from the University of Oxford and is also a two-time world champion lightweight rower who competed on the British International Rowing Team. Together, Drs. Verdin and Stubbs serve as co-hosts of Season 3 of the Live Better Longer podcast, bringing their expertise and passion for longevity science to conversations with leading researchers, clinicians, and innovators in the field of healthy aging. Support the show (https://www.buckinstitute.org/donate/)https://www.youtube.com/embed/m4hrM3l4JqY2026-06-24T12:15:26.000Z https://longevityprogress.com/videos/brad-younggren-filtering-out-aging-uUlpcTw_Z3k2026-06-10T12:21:43.000Zmonthly0.5https://i.ytimg.com/vi/uUlpcTw_Z3k/hqdefault.jpgBrad Younggren: Filtering Out AgingWhat if removing and replacing part of your blood could turn back some of the measurable signs of aging? Brianna Stubbs talks with Dr. Brad Younggren — emergency physician, former Army doctor, and CEO of Circulate Health — about therapeutic plasma exchange (TPE). They cover how the procedure works, what the blinded Circulate trial found (including an average 2.6-year reduction in biological age over three months), TPE's unique potential to clear microplastics from the bloodstream, and the broader impact of our environment—the exposome—on human healthspan. Brad Younggren, MD, is CEO and co-founder of Circulate Health, a company dedicated to improving human healthspan. A former U.S. Army physician, Dr. Younggren served as a combat physician in Iraq and was awarded a Bronze Star and Combat Medical Badge. An emergency medicine specialist and seasoned healthcare executive, Younggren has led teams at the cutting edge of medicine for decades. Most recently, he was President and Chief Medical Officer at 98point6, where he led the development and launch of AI-powered primary care solutions. He previously served as Chief Medical Officer at Cue Health, Shift Labs, and Mobisante. At Circulate, Younggren leads an expert team of clinicians and scientists working to harness the potential of therapeutic plasma exchange to advance health and longevity. Support the show (https://www.buckinstitute.org/donate/)https://www.youtube.com/embed/uUlpcTw_Z3k2026-06-10T12:21:43.000Z https://longevityprogress.com/videos/may-6-2026-scientific-wellness-to-unlock-longer-healthier-lives-nathan-suXdKSZGI2o2026-05-06T21:57:43.000Zmonthly0.5https://i.ytimg.com/vi/suXdKSZGI2o/hqdefault.jpgMay 6, 2026: Scientific Wellness to Unlock Longer, Healthier Lives; Nathan Price, PhDSpeaker: Nathan Price, PhD; Professor and Co-Director, Center for Human Healthspan, Buck Institutehttps://www.youtube.com/embed/suXdKSZGI2o2026-05-06T21:57:43.000Z https://longevityprogress.com/videos/aging-in-the-wild-afar-webinar-czNfAAnISZY2026-05-05T17:30:46.000Zmonthly0.5https://i.ytimg.com/vi/czNfAAnISZY/hqdefault.jpgAging in the Wild | AFAR WebinarAging in the Wild Aging in the Wild: What Beavers, Mole Rats, Tortoises, Clams, and Other Exceptionally Long-Lived Species Can Teach Human Beings about Living Longer, Healthier Lives | AFAR and Nathan Shock Centers Webinar (May 1, 2026) In this webinar presented by AFAR and Nathan Shock Centers Coordinating Center (NSC3) , AFAR Scientific Director Steven N. Austad, PhD, moderated a discussion exploring exceptional animal longevity and what it could mean for human aging. Upstate New York Nathan Shock Center Director Vera Gorbunova, PhD, and Live Animal Resource Core Leader at the Upstate New York Nathan Shock Center Andrei Seluanov, PhD, shared their perspectives on comparative biology. Learn more about aging research: https://www.afar.org/ Follow AFAR on social media: Facebook: American Federation for Aging Research LinkedIn: American Federation for Aging Researchhttps://www.youtube.com/embed/czNfAAnISZY2026-05-05T17:30:46.000Z https://longevityprogress.com/videos/cracking-the-secretome-code-ku4dw_CMgkE2026-04-01T12:18:48.000Zmonthly0.5https://i.ytimg.com/vi/ku4dw_CMgkE/hqdefault.jpgCracking the Secretome CodeIn this episode, Buck scientist Brianna Stubbs sits down with Hanadie Yousef, Co-Founder of Juvena Therapeutics, to discuss the cutting-edge of longevity science. Dr. Yousef shares how Juvena is leveraging AI and the secretome—the proteins secreted by stem cells—to develop therapies that target muscle wasting and promote tissue regeneration. From the potential and risks of GLP-1 drugs to the role of AKT signaling in muscle health, this conversation explores how we can move beyond "snake oil" and into a future where science-based therapies help us stay younger, longer. Dr. Hanadie Yousef is a scientist, entrepreneur, seasoned executive, and global thought leader in AI-driven regenerative medicine and longevity. With over two decades of experience in biomedical research, she is the Co-Founder of Juvena Therapeutics, where she served as CEO, CFO, and Board Chair from 2017 to 2025. Since the company’s incorporation, she pioneered its evolution from a platform-driven concept into a venture-backed, clinical-stage biotechnology leader. Under her leadership, Juvena secured over $105M in venture capital, non-dilutive grants, and partnerships, and developed a proprietary pipeline of tissue-restorative biologics for muscle and metabolic diseases. Support the show (https://www.buckinstitute.org/donate/)https://www.youtube.com/embed/ku4dw_CMgkE2026-04-01T12:18:48.000Z https://longevityprogress.com/videos/cynthia-kenyon-switching-on-resilience-Ijr-ydVczgk2026-03-18T12:23:26.000Zmonthly0.5https://i.ytimg.com/vi/Ijr-ydVczgk/hqdefault.jpgCynthia Kenyon: Switching on ResilienceEric Verdin sits down with Dr. Cynthia Kenyon, a true pioneer in the field of geroscience and the Vice President of Aging Research at Calico. Dr. Kenyon recounts the revolutionary discovery that aging is not merely a process of "wearing out," but is a genetically regulated biological program. In 1993, Cynthia’s pioneering discovery that a single-gene mutation could double the lifespan of C. elegans roundworms while preserving function sparked an intensive study of the molecular biology of aging. The conversation explores how these findings translate from worms to mammals, the potential of drugs like Ozempic and Acarbose to extend human healthspan, and Dr. Kenyon’s proposal for a "World Healthspan Organization" to fund large-scale clinical trials for off-patent, low-cost compounds that currently lack traditional industry incentives. Cynthia Kenyon graduated valedictorian in chemistry and biochemistry from the University of Georgia in 1976 and received her PhD from MIT in 1981. She then did postdoctoral studies with Nobel laureate Sydney Brenner at the MRC Laboratory of Molecular Biology in Cambridge, UK. In 1986, she joined the University of California, San Francisco as a Professor of Biochemistry and Biophysics. Dr. Kenyon is a member of the US National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of Medicine and she is a past president of the Genetics Society of America. She is now the Vice President of Aging Research at Calico. Support the show (https://www.buckinstitute.org/donate/)https://www.youtube.com/embed/Ijr-ydVczgk2026-03-18T12:23:26.000Z https://longevityprogress.com/videos/unpacking-biohacking-for-longevity-afar-webinar-0jr5f9HGdJE2026-03-17T13:30:01.000Zmonthly0.5https://i.ytimg.com/vi/0jr5f9HGdJE/hqdefault.jpgUnpacking Biohacking for Longevity | AFAR WebinarUnpacking Biohacking for Longevity | AFAR Webinar (March 12, 2026) Biohacking is a rapidly rising approach to extending health that combines science, lifestyle changes, smart tools, proactive diagnostics, and actionable biodata, with aims of "optimizing" cellular function and vitality. At its most accessible, biohacking approaches include tracking through wearables and biosensors and lifestyle interventions like diet and sleep. At its most extreme, other biohacking strategies include conducting self-experimentation outside of a lab setting or implanting technology to enhance physical abilities. Proponents pose that biohacking can help advance personalized medicine to extend healthspan, while skeptics raise concerns of ethics, access, and scientific rigor. The upcoming free webinar is a highly scientific, evidence-based discussion on the topic with leading medical doctors and academics. In this webinar moderated by AFAR board member Sergey Young, of the BOLD Longevity Growth Fund, experts and innovators featured are 2025 AFAR Cristofalo winner Daniel W Belsky, PhD; Mark Kotter, PhD; Helen Messier, PhD, MD, IFMCP; and AFAR President Thomas A. Rando, MD, PhD. Learn more about aging research: https://www.afar.org/ Follow AFAR on social media: Facebook: American Federation for Aging Research LinkedIn: American Federation for Aging Researchhttps://www.youtube.com/embed/0jr5f9HGdJE2026-03-17T13:30:01.000Z https://longevityprogress.com/videos/the-potential-of-geroscience-from-economic-gains-social-returns-and-et-2pTxz2EtC242026-01-21T18:26:00.000Zmonthly0.5https://i.ytimg.com/vi/2pTxz2EtC24/hqdefault.jpgThe Potential of Geroscience: from Economic Gains, Social Returns, & Ethical Concerns | AFAR WebinarThe Potential of Geroscience: from Economic Gains to Social Returns and Ethical Concerns | AFAR Webinar (October 21, 2025) In this webinar, Boston Globe Ideas Editor Brian Bergstein moderated a discussion on the economic gains, health rewards, and social returns that geroscience can generate. AFAR President Thomas A. Rando, MD, PhD, and AFAR Scholar-in-Residence Raiany Romanni, PhD, shared their perspectives on biology, bioethics, economics, and innovation, exploring biomedical research, social planning, and the socioeconomic impact of geroscience. Learn more about aging research: https://www.afar.org/ Follow AFAR on social media: Facebook: American Federation for Aging Research LinkedIn: American Federation for Aging Researchhttps://www.youtube.com/embed/2pTxz2EtC242026-01-21T18:26:00.000Z https://longevityprogress.com/videos/the-state-of-gerotherapeutics-next-gen-interventions-to-extend-healthy-e62fDE9sxaQ2026-01-21T18:20:18.000Zmonthly0.5https://i.ytimg.com/vi/e62fDE9sxaQ/hqdefault.jpgThe State of Gerotherapeutics: Next Gen Interventions to Extend Healthy Living | AFAR WebinarThe State of Gerotherapeutics: Next Gen Interventions to Extend Healthy Living | AFAR Webinar (September 22, 2025) Leaders from the academic, clinical, and private sectors clarified how both repurposing existing drugs and developing novel compounds can extend healthspan; unpacked the need for human trials, the importance of an FDA indication for aging, as well as the risks in off-label use and harm of radical life extension claims; counter myths and misinformation with accurate expectations; explored how drug and lifestyle interventions work together to extend healthspan; and more. In this webinar, New York Times health reporter Dana G. Smith, PhD, moderated a discussion on the current state of existing and emerging drug interventions to extend healthspan with Nir Barzilai, MD (President, Academy of Health and Lifespan Research); Rafael de Cabo, PhD (Chief, Translational Gerontology Branch of the National Institute on Aging); Sara Espinoza, MD (Director, Center for Translational Geroscience at Cedars-Sinai Medical Center); Kristen Fortney, PhD (CEO and Co-Founder, BioAGE Labs); and Carolina Solis-Herrera, MD (Division Chief & Associate Professor, Division of Endocrinology, UT Health San Antonio School of Medicine). Learn more about aging research: https://www.afar.org/ Follow AFAR on social media: Facebook: American Federation for Aging Research LinkedIn: American Federation for Aging Researchhttps://www.youtube.com/embed/e62fDE9sxaQ2026-01-21T18:20:18.000Z https://longevityprogress.com/videos/mhealth-for-healthy-aging-afar-webinar-ExLdSShB1iU2026-01-21T17:44:57.000Zmonthly0.5https://i.ytimg.com/vi/ExLdSShB1iU/hqdefault.jpgmHealth for Healthy Aging | AFAR WebinarmHealth for Healthy Aging | AFAR Webinar (June 25, 2025) mHealth, or mobile health, can play a significant role in promoting healthy aging by leveraging technology to support self-management of chronic conditions, improve physical activity, and enhance overall well-being and connection for older adults. In this webinar moderated by AFAR board member Sergey Young, of the BOLD Longevity Growth Fund, experts Eduardo N. Chini, MD, PhD, Michael Hufford, PhD, Michael Levin, PhD, and AFAR President Thomas A. Rando, MD, PhD explored how Mobile technologies at the forefront of personalized medicine, supporting proactive health management and can improve outcomes for various conditions. Learn more about aging research: https://www.afar.org/ Follow AFAR on social media: Facebook: American Federation for Aging Research LinkedIn: American Federation for Aging Researchhttps://www.youtube.com/embed/ExLdSShB1iU2026-01-21T17:44:57.000Z https://longevityprogress.com/videos/emerging-technologies-and-aging-research-bioprinting-organ-regeneratio-kAvuFpar3mo2026-01-21T16:57:49.000Zmonthly0.5https://i.ytimg.com/vi/kAvuFpar3mo/hqdefault.jpgEmerging Technologies and Aging Research: Bioprinting, Organ Regeneration, and Beyond | AFAR WebinarEmerging Technologies and Aging Research: Bioprinting, Organ Regeneration, and Beyond | AFAR Webinar (March 20, 2025) Innovations in organ and tissue regeneration are rapidly advancing and hold great promise for supporting healthy aging. New therapies can now grow ectopic organs within the body, while 3D‑printing technologies are creating complex, functional tissues from living cells. In this webinar, moderated by AFAR Board Member Sergey Young of the BOLD Longevity Growth Fund, experts Eduardo N. Chini, MD, PhD (Mayo Clinic); Michael Hufford, PhD (LyGenesis); Michael Levin, PhD (Morphoceuticals and Tufts University); and AFAR President Thomas A. Rando, MD, PhD (UCLA) explored how these emerging technologies could transform organ transplantation, drug testing, and regenerative medicine. They also highlighted how new partnerships between academia and biotech may accelerate personalized medicine for all. Learn more about aging research: https://www.afar.org/ Follow AFAR on social media: Facebook: American Federation for Aging Research LinkedIn: American Federation for Aging Researchhttps://www.youtube.com/embed/kAvuFpar3mo2026-01-21T16:57:49.000Z https://longevityprogress.com/videos/how-realistic-is-a-100-year-life-expectancy-and-why-does-it-matter-afa-cvcguqGuy5k2026-01-21T15:53:38.000Zmonthly0.5https://i.ytimg.com/vi/cvcguqGuy5k/hqdefault.jpgHow Realistic is a 100-Year Life Expectancy and Why Does it Matter? | AFAR WebinarHow Realistic is a 100-Year Life Expectancy and Why Does it Matter? | AFAR Webinar (October 22, 2024) The field of aging research has advanced alongside medical interventions that have helped many live longer than generations before us. For scientists, journalists, and consumers alike, this has sparked a fascination with life expectancy: at the rate of modern medical innovations, will more of us live into our 100s and beyond? In this webinar, AFAR presented a conversation between public health and gerontology expert S. Jay Olshansky, PhD, and longevity global economist Andrew J. Scott, DPhil, moderated by AFAR Scientific Director Steven N. Austad, PhD to explore this question further. Learn more about aging research: https://www.afar.org/ Follow AFAR on social media: Facebook: American Federation for Aging Research LinkedIn: American Federation for Aging Researchhttps://www.youtube.com/embed/cvcguqGuy5k2026-01-21T15:53:38.000Z https://longevityprogress.com/videos/ai-for-longevity-drug-discovery-breakthrough-and-challenges-afar-webin-NF-mo26NzbI2026-01-21T15:34:15.000Zmonthly0.5https://i.ytimg.com/vi/NF-mo26NzbI/hqdefault.jpgAI For Longevity Drug Discovery: Breakthrough and Challenges | AFAR WebinarAI For Longevity Drug Discovery: Breakthrough and Challenges | AFAR Webinar (June 18, 2024) Artificial Intelligence (AI) technologies are transforming biotech landscape by accelerating the discovery of new drug candidates, predicting molecular behaviors, and optimizing clinical trials, and ultimately amplifying the development of promising therapeutics to extend health and delay disease as we grow older. In this webinar, curated by AFAR Board Member Sergey Young (CEO of the Longevity Vision Fund), moderator Kristen Fortney, PhD, of BioAge is joined by Hanadie Yousef, PhD, of Juvena Therapeutics, Alex Zhavoronkov, PhD, of Insilico Medicine, and Ben Blue, PhD, of Ora Biomedical, Inc. to discuss the real-world applications of AI in drug discovery, as well as the challenges and breakthroughs it presents. Learn more about aging research: https://www.afar.org/ Follow AFAR on social media: Facebook: American Federation for Aging Research LinkedIn: American Federation for Aging Researchhttps://www.youtube.com/embed/NF-mo26NzbI2026-01-21T15:34:15.000Z https://longevityprogress.com/videos/whats-so-super-about-superagers-and-what-can-we-learn-from-them-afar-l-Xx80myfc7U82026-01-21T14:37:48.000Zmonthly0.5https://i.ytimg.com/vi/Xx80myfc7U8/hqdefault.jpgWhat's so Super about SuperAgers? (& what can we learn from them!) | AFAR Live Better Longer WebinarWhat's so Super about Superagers? (And what can we learn from them!) | AFAR Live Better Longer Webinar (May 29, 2024) All of us may not live into our nineties or beyond, but all of us can learn from those who have. One path to gaining scientific knowledge about healthy aging is to look at those who have lived past their 95th birthday—people known as SuperAgers. In this webinar, Kaitlyn Phoenix, Deputy Editor, Hearst Health Newsroom, will speak with Nir Barzilai, MD, Co-Investigator of the AFAR SuperAgers Family Study, and 95-year-old Florida resident and study enrollee Natalie Ramirez. Learn more about the SuperAgers Initiative here: https://www.afar.org/superagers/ Join the SuperAgers Community here: https://www.afar.org/superagerscommunity Enroll in the SuperAgers Family Study here: https://www.superagersstudy.org/ Learn more about aging research: https://www.afar.org/ Follow AFAR on social media: Facebook: American Federation for Aging Research LinkedIn: American Federation for Aging Researchhttps://www.youtube.com/embed/Xx80myfc7U82026-01-21T14:37:48.000Z https://longevityprogress.com/videos/live-stronger-longer-muscle-physiology-and-healthy-aging-afar-webinar-R6RvwBdDib02026-01-20T21:29:25.000Zmonthly0.5https://i.ytimg.com/vi/R6RvwBdDib0/hqdefault.jpgLive Stronger Longer: Muscle Physiology and Healthy Aging | AFAR WebinarLive Stronger Longer: Muscle Physiology and Healthy Aging | AFAR Webinar (November 8, 2023) Scientists are actively working to understand how exercise can improve muscle health and reduce skeletal muscle decline as we age. In a conversation-style webinar, leading muscle physiology expert Kevin Murach, PhD, joins Prevention Editor-in-Chief Sarah Smith to discuss the science behind exercise, muscles, and healthy aging. Learn more about aging research: https://www.afar.org/ Follow AFAR on social media: Facebook: American Federation for Aging Research LinkedIn: American Federation for Aging Researchhttps://www.youtube.com/embed/R6RvwBdDib02026-01-20T21:29:25.000Z https://longevityprogress.com/videos/beginning-in-biotech-insights-from-insiders-afar-webinar-xaWIkCszmxA2026-01-20T21:24:03.000Zmonthly0.5https://i.ytimg.com/vi/xaWIkCszmxA/hqdefault.jpgBeginning in Biotech: Insights from Insiders | AFAR WebinarBeginning in Biotech: Insights from Insiders | AFAR Webinar (October 3, 2023) Today more than ever, biomedical researchers have more opportunities to bring to market new therapeutics and interventions to extend healthspan. In this webinar, AFAR Grantee Kristen Fortney of BioAge, Jim Mellon of Juvenescence, James Peyer of Cambrian Biopharma, and moderator Sergey Young of Longevity Vision Fund reveal what they look for in scientific collaborators and proposals, share tips on investor relations and business planning, and field your questions on moving research from the labs into our lives. Learn more about aging research: https://www.afar.org/ Follow AFAR on social media: Facebook: American Federation for Aging Research LinkedIn: American Federation for Aging Researchhttps://www.youtube.com/embed/xaWIkCszmxA2026-01-20T21:24:03.000Z https://longevityprogress.com/videos/5-breakthroughs-changing-aging-afar-live-better-longer-webinar-lQVetTf6Dng2026-01-20T21:08:48.000Zmonthly0.5https://i.ytimg.com/vi/lQVetTf6Dng/hqdefault.jpg5 Breakthroughs Changing Aging | AFAR Live Better Longer Webinar5 Breakthroughs Changing Aging | AFAR Live Better Longer Webinar (June 21, 2023) Today, a range of promising breakthroughs are changing the way we age, for the better. In this webinar, Prevention’s Editor-in-Chief Sarah Smith will be joined by AFAR Senior Scientific Director Steven N. Austad, PhD, to discuss the five most exciting science-backed innovations that are poised to help us all live healthier, longer. Learn more about aging research: https://www.afar.org/ Follow AFAR on social media: Facebook: American Federation for Aging Research LinkedIn: American Federation for Aging Researchhttps://www.youtube.com/embed/lQVetTf6Dng2026-01-20T21:08:48.000Z https://longevityprogress.com/videos/the-benifits-of-isoleucine-restriction-on-lifespan-and-health-by-dr-ca-nRbWZV14v7Q2023-06-06T21:56:35.000Zmonthly0.5https://i.ytimg.com/vi/nRbWZV14v7Q/hqdefault.jpgThe benifits of isoleucine restriction on lifespan and health by Dr. Cara GreenThe benifits of isoleucine restriction on lifespan and health by Dr. Cara Greenhttps://www.youtube.com/embed/nRbWZV14v7Q2023-06-06T21:56:35.000Z https://longevityprogress.com/videos/sex-dimorphic-regulation-of-innate-immunity-during-aging-by-berenice-b-lnTPf45YXS82023-05-24T22:02:16.000Zmonthly0.5https://i.ytimg.com/vi/lnTPf45YXS8/hqdefault.jpgSex-Dimorphic Regulation of Innate Immunity During Aging by Berenice BenayounSex-Dimorphic Regulation of Innate Immunity During Aging by Berenice Benayounhttps://www.youtube.com/embed/lnTPf45YXS82023-05-24T22:02:16.000Z